Intermittent PTH administration builds bone mass and prevents fractures, but its mechanism of action is unclear. We genetically deleted the PTH/PTHrP receptor (PTH1R) in mesenchymal stem cells using Prx1Cre and found low bone formation, increased bone resorption, and high bone marrow adipose tissue (BMAT). Bone marrow adipocytes traced to Prx1 and expressed classic adipogenic markers and high r...

The recombinant parathyroid hormone (PTH) Teriparatide is the only therapy for postmenopausal osteoporosis that increases bone mass (i.e., is anabolic). Its therapeutic action depends on a short “burst” of PTH in the circulation followed by a rapid return to normal levels; if PTH levels remain high, bone loss occurs (i.e., the effect is catabolic) (Frolik et al., 2003). This occurs because PTH ...

Tooth eruption is a complex process, during which series of factors can cause failure it. Among this, primary (PFE) non-syndromic condition that leads to an incomplete tooth despite the presence clear pathway. The aim this narrative review provide overall view about clinical considerations, genetics-related aspects, and possible treatments PFE based on latest findings. A literature search using...

INTRODUCTION Aging decreases chondrogenesis, bone formation, callus vascularization and remodeling during facture healing in mice, which is associated with reduced cyclooxygenase-2 (COX-2) expression, and is restored by administration of an EP4 agonist. Activation of the EP4 receptor stimulates cAMP and activation of the protein kinase A (PKA) signaling pathway. These findings suggest that enha...